

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
Wolfgang HEIL et al.

Serial No.: 09/757,688

Filed: January 11, 2001

For: DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

RECEIVED
#10
SEP 25 2001
TECH CENTER 1990/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

☒ Copies of materials listed and attached were cited in related application Serial No. 09/484,026.

CA 2188907 corresponds to EP 0770388 and US 4,621,079 corresponds to EP 0148724.

☐ Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed _____.

☐ Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.

☐ Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

☒ No fee is required for this Information Disclosure Statement because:

☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;

☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;

☐ This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

☐ A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).

☐ A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION


☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If appropriate, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,


Jennifer Branigan
Registration No.40,921
Patent Agent

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: **25 September 2001**

Jjb:K:\Plovin\2 A\Information Disclosure Statement.doc